vimarsana.com
Home
Live Updates
ASCO 2024: A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03) : comparemela.com
ASCO 2024: A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)
ASCO 2024 results of a multicenter phase II trial of modified FOLFIRINOX for the first-line treatment of advanced urachal cancer (ULTMA; KCSG GU20-03), Urachal cancer is a rare malignancy accounting for 1% of bladder cancers.
Related Keywords
Chicago ,
Illinois ,
United States ,
Toronto ,
Ontario ,
Canada ,
South Korea ,
Seoul ,
Soult Ukpyolsi ,
American ,
Jae Lyun Lee ,
Md Anderson Cancer Center ,
Society Of Urologic Oncology ,
American Society Of Clinical Oncology ,
Twitter ,
University College Of Medicine ,
Asan Medical Center ,
University Of Toronto ,
Clinical Oncology ,
Annual Meeting ,
University College ,
Rashid Sayyid ,
Urologic Oncology ,
Clinical Fellow ,
Anderson Cancer Center ,
Patients With Relapsed ,
Metastatic Malignant Urachal ,
comparemela.com © 2020. All Rights Reserved.